Search Results - collaboration+sought+%3e+materials+available

71 Results Sort By:
RS-1 Knockout Mouse Model for X-Linked Retinoschisis (XLRS) Research
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a transgenic mouse model for X-linked retinoschisis (XLRS). This technology includes a transgenic mouse model specifically designed to study X-linked retinoschisis (XLRS) disease by interrupting exon 1 of the Rs1 gene. XLRS is a genetic condition...
Published: 6/24/2026   |   Updated: 6/24/2026   |   Inventor(s): Paul Sieving, Yong Zeng, Ronald Bush
Keywords(s):  
Category(s): Application > Research Materials, Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Collaboration Sought > Materials Available, ResearchProducts > Animal Models, TherapeuticArea > Ophthalmology, TherapeuticArea > Rare/Neglected Diseases
Myocilin Mutant Cell Lines for Glaucoma Research and Drug Screening
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of innovative therapeutic strategies targeting myocilin mutations in glaucoma. This technology includes the development of HEK293 cell lines expressing wild-type and Y437H mutant myocilin, which can be used to study the pathogenic mechanisms...
Published: 6/18/2026   |   Updated: 6/16/2026   |   Inventor(s): Myungkuk Joe
Keywords(s):  
Category(s): Application > Research Materials, Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Collaboration Sought > Materials Available, ResearchProducts > Human Cell Lines, TherapeuticArea > Ophthalmology
Targeted Disruption of Rpe65 Gene for Retinal Disease Research
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a targeted disruption of the Rpe65 gene in mice, a novel model for studying retinal diseases and testing potential therapies. This technology includes the targeted disruption of the Rpe65 gene in mice, which serves as a crucial model for...
Published: 6/18/2026   |   Updated: 6/16/2026   |   Inventor(s): Thomas Redmond, Karl Pfeifer
Keywords(s):  
Category(s): Application > Research Materials, Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Collaboration Sought > Materials Available, ResearchProducts > Animal Models, TherapeuticArea > Ophthalmology, TherapeuticArea > Rare/Neglected Diseases
MmabΔ3-7/Δ3-7 mouse model of metabolism of cobalamin associated B (MMAB) for the study of methylmalonic acidemia (MMA)
Isolated Methylmalonic Acidemia (MMA) comprises a relatively common and heterogeneous group of inborn errors of metabolism. One cause of isolated MMA is genetic deficiency of the enzyme ATP:cob(I)alamin adenosyltransferase encoded by the metabolism of cobalamin associated B (MMAB) gene. MMAB deficiency, also called the cobalamin B type (cblB) of MMA...
Published: 5/28/2026   |   Updated: 5/28/2026   |   Inventor(s): Charles Venditti, Eun-Young Choi
Keywords(s):  
Category(s): Application > Research Materials, TherapeuticArea > Rare/Neglected Diseases, ResearchProducts, ResearchProducts > Animal Models, Collaboration Sought, Collaboration Sought > Licensing, Collaboration Sought > Collaboration, Collaboration Sought > Materials Available
A Novel Strategy to Produce 6-cys Proteins Based on Pfs230D1 Domain Fusions
The Plasmodium parasite has a complex lifecycle during human infection and in the mosquito vector. Most advanced malaria vaccine candidates can confer only partial, short-term protection in malaria-endemic areas. A means of breaking the transmission of malaria to subsequent individuals could prevent a significant amount of human disease. The primary...
Published: 5/14/2026   |   Updated: 5/14/2026   |   Inventor(s): Patrick Duffy, Jonathan Renn
Keywords(s):  
Category(s): Application, Application > Research Materials, Application > Therapeutics, Application > Vaccines, Collaboration Sought, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Collaboration Sought > Materials Available, ResearchProducts > Sequences, TherapeuticArea > Immunology, TherapeuticArea > Infectious Disease
Anti-Nucleoprotein Crimean-Congo Hemorrhagic Fever Virus Monoclonal Antibodies for Assay Creation
Crimean-Congo hemorrhagic fever (CCHF) is the most widespread form of viral hemorrhagic fever, found in Eastern and Southern Europe, the Mediterranean, northwestern China, central Asia, Africa, the Middle East, and the Indian subcontinent. Typically beginning with non-specific fever, myalgia, nausea, diarrhea, and general malaise, symptoms of infection...
Published: 7/3/2025   |   Updated: 7/3/2025   |   Inventor(s): Daniel Douek, David Hawman, Leonid Serebryannyy, Noemia Santana Lima, Chaim Schramm, Sarah Smith (Kerscher), Amy Henry, Alicen Spaulding
Keywords(s):  
Category(s): Application, Application > Diagnostics, Collaboration Sought, Collaboration Sought > Licensing, Collaboration Sought > Materials Available, ResearchProducts > Antibodies, TherapeuticArea, TherapeuticArea > Infectious Disease, TherapeuticArea > Immunology, TherapeuticArea > Rare/Neglected Diseases
EV-D68 Monoclonal Antibodies Isolated from Immunized Rhesus Macaques
Enterovirus D68 (EV-D68) has been linked to the widespread outbreaks of respiratory illness and acute flaccid myelitis (AFM) in the United States and Europe in 2014, 2016, and 2018. Although EV-D68 is now the most frequently encountered enterovirus (41.1% of cases), with an estimated global prevalence of 4%, there are no specific, FDA-approved therapeutic...
Published: 6/18/2026   |   Updated: 7/2/2025   |   Inventor(s): Tracy Ruckwardt, Daniel Moss, Peter Krug, Masaru Kanekiyo
Keywords(s):  
Category(s): Application, Application > Diagnostics, Application > Therapeutics, Application > Vaccines, Collaboration Sought, Collaboration Sought > Licensing, Collaboration Sought > Materials Available, ResearchProducts, ResearchProducts > Antibodies, TherapeuticArea, TherapeuticArea > Immunology, TherapeuticArea > Infectious Disease
Discovery of potent and selective D3 antagonist with alleviated hERG liability and optimized pharmacokinetic properties
One of the most challenging hurdles in creating safe and effective new medicines for many diseases is finding drugs that are effective without causing off-target cardiac issues, such as cardiac arrythmias. In collaboration with NIDA, scientists at NCATS have developed a series of novel and highly specific dopamine D3 receptor agonists and antagonists...
Published: 11/14/2025   |   Updated: 6/13/2025   |   Inventor(s): Khalida Shamim, Wenwei Huang, Wei Zheng, Catherine Chen, Xiuli Huang, Xin Hu, Xin Xu, Pranav Shah, Elias Padilha, Philip Sanderson, Amy Newman
Keywords(s):  
Category(s): Application > Therapeutics, Collaboration Sought > Licensing, Collaboration Sought > Materials Available, TherapeuticArea > Neurology, TherapeuticArea > Psychiatry/Mental Health
Antibodies to TMC1 Protein for Hearing Loss
This technology includes antibodies for TMC1 protein as a treatment for hearing loss. TMC1 is one of the common genes causing hereditary hearing loss. Our laboratory used synthetic peptides corresponding to the TMC1 protein to immunize rabbits. The resulting antisera were shown to bind to TMC1 protein expressed in heterologous expression systems. TMC1...
Published: 5/19/2025   |   Updated: 5/19/2025   |   Inventor(s): Andrew Griffith, Tomoko Makishima, Valentina Labay
Keywords(s):  
Category(s): Application > Research Materials, Application > Therapeutics, ResearchProducts > Antibodies, Collaboration Sought > Licensing, Collaboration Sought > Materials Available
Blocking CD38 using Daratumumab F(ab)2 to Protect Natural Killer Cells from Daratumumab-induced Apoptosis and Cell Death for the Treatment of Multiple Myeloma
This technology includes the method of blocking CD38 in expanded natural killer (NK) cell therapy in combination with daratumumab in patients with multiple myeloma. Our in vitro studies have already confirmed the addition of NK cells to myeloma cells that have been exposed to daratumumab enhances myeloma killing compared to single agent treatment. Studies...
Published: 8/12/2024   |   Updated: 3/26/2024   |   Inventor(s): Richard Childs, Jorge Luis Espinoza-Calderon, Maria Berg
Keywords(s):  
Category(s): Application > Research Materials, Collaboration Sought > Licensing, Collaboration Sought > Materials Available, ResearchProducts > Human Cell Lines, TherapeuticArea > Oncology
1 2 3 4 5 6 7 8